Aleglitazar
Aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator ) with affinity to PPARα and PPARγ, which is being developed by Hoffmann–La Roche for the treatment of type II diabetes. It is currently in phase II clinical trials.
read more [+]| Systematic (IUPAC) name | (2S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-7-benzothiophenyl]propanoic acid |
|---|---|
| CAS number | 475479-34-6 |
| ATC code | |
| PubChem | 10274777 |
| DrugBank | |
| Formula: | C24H23NO5S |
| Molecular mass | 437.50812 g/mol |
| Assay/Purity | Typically NLT 98% |
